No new diabetes-relevant regulatory decision has appeared since the last sweep. Reported as quiet rather than padded with something older dressed up as news.
The most recent decisions of consequence remain the batch of 11 August, all supplements to already-approved extended-release combination products: the linagliptin-metformin and sitagliptin-metformin combinations, and the empagliflozin-based triple combination. Supplements of this kind are changes to an existing application — manufacturing, labelling, or a new strength — rather than new medicines, and none of them alters how you prescribe.
What to do about it: nothing. A quiet regulatory day is worth stating plainly, because the alternative is a reader learning to skim this section.
- No new approvals, label changes or safety communications since the last sweep
- The 11 August clearances were supplements to existing applications, not new medicines
- No action required on any current prescription
- Safety communications, when they come, arrive as alerts rather than waiting for the morning edition
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free